INSR and breast cancer: In this regard, a phase II study (NCT01205685) investigated in ER-positive BC patients the potential antitumor activity of a dual IGF-1R/IR tyrosine kinase inhibitor, namely, linsitinib (OSI-906), used in combination with hormone therapy.